Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors
- First Posted Date
- 2008-02-05
- Last Posted Date
- 2017-03-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 34
- Registration Number
- NCT00607048
- Locations
- 🇺🇸
Pfizer Investigational Site, San Antonio, Texas, United States
A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.
Phase 2
Completed
- Conditions
- Liver Cancer
- Interventions
- First Posted Date
- 2008-01-31
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 51
- Registration Number
- NCT00605722
A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for Maintenance Treatment of Anemia in Kidney Transplant Recipients.
Phase 3
Completed
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
- First Posted Date
- 2008-01-31
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 71
- Registration Number
- NCT00605345
A Study of Intravenous Mircera (C.E.R.A or Methoxy Polyethylene Glycol-epoetin Beta) for the Maintenance Treatment of Hemodialysis Participants With Chronic Renal Anemia
Phase 3
Completed
- Conditions
- Anemia
- Interventions
- First Posted Date
- 2008-01-31
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 101
- Registration Number
- NCT00605293
A Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: PlaceboBiological: RituximabDrug: Folic acid or folate
- First Posted Date
- 2007-12-21
- Last Posted Date
- 2015-04-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 185
- Registration Number
- NCT00578305
A Study of Subcutaneous Mircera, Versus no Erythropoiesis-Stimulating Agent (ESA) Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant
Phase 4
Terminated
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]Drug: Supportive treatment
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1
- Registration Number
- NCT00576602
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.
Phase 2
Withdrawn
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00577109
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.
Phase 4
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 60
- Registration Number
- NCT00576433
GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2014-08-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 175
- Registration Number
- NCT00576758
A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia.
Phase 3
Completed
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 200
- Registration Number
- NCT00576303
© Copyright 2025. All Rights Reserved by MedPath